- Home
- ERII vs ABUS Comparison
ERII vs ABUS Comparison
Compare ERII & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ERII | ABUS |
|---|---|---|
| Founded | 1992 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 740.3M | 848.1M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | ERII | ABUS |
|---|---|---|
| Price | $14.30 | $4.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $18.33 | $5.00 |
| AVG Volume (30 Days) | 534.8K | ★ 1.1M |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.56 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $135,191,000.00 | $14,606,000.00 |
| Revenue This Year | $5.93 | $125.30 |
| Revenue Next Year | $8.97 | N/A |
| P/E Ratio | $41.28 | ★ N/A |
| Revenue Growth | 0.10 | ★ 116.64 |
| 52 Week Low | $10.86 | $2.71 |
| 52 Week High | $18.32 | $5.10 |
Technical Indicators
Market Signals| Indicator | ERII | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 53.32 |
| Support Level | $14.18 | $4.09 |
| Resistance Level | $14.91 | $4.47 |
| Average True Range (ATR) | 0.44 | 0.19 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 57.80 | 76.36 |
Price Performance
Historical ComparisonAbout ERII Energy Recovery Inc.
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.